These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 21417852)
1. Development of targeted therapy for squamous cell carcinomas of the head and neck. Burgos-Tiburcio A; Santos ES; Arango BA; Raez LE Expert Rev Anticancer Ther; 2011 Mar; 11(3):373-86. PubMed ID: 21417852 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel in the management of patients with head and neck squamous cell carcinoma. Bernier J; Vrieling C Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449 [TBL] [Abstract][Full Text] [Related]
3. [Use of docetaxel in treatment of squamous-cell carcinoma of head and neck]. Subramanian S; Kanagavel D; Petenko NN; Orlova KV; Samoĭlenko IV; Demidov LV Vopr Onkol; 2011; 57(4):421-6. PubMed ID: 22191228 [No Abstract] [Full Text] [Related]
4. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Kovács AF; Mose S; Böttcher HD; Bitter K Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy in the management of squamous cell carcinoma of the head and neck. Roman E; Raez LE; Santos ES Expert Rev Anticancer Ther; 2006 Sep; 6(9):1205-15. PubMed ID: 17020455 [TBL] [Abstract][Full Text] [Related]
6. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Marur S; Forastiere AA Curr Opin Oncol; 2010 May; 22(3):206-11. PubMed ID: 20216313 [TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapies in all histologies of head and neck cancers: an update. Razak AR; Siu LL; Le Tourneau C Curr Opin Oncol; 2010 May; 22(3):212-20. PubMed ID: 20173639 [TBL] [Abstract][Full Text] [Related]
8. Concurrent weekly docetaxel and hyperfractionated radiotherapy for advanced head and neck cancer. Matsumoto F; Karasawa K; Itoh S; Toda M; Haruyama T; Furukawa M; Ikeda K Anticancer Res; 2006; 26(5B):3781-6. PubMed ID: 17094401 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy: to use or not to use? That is the question. Brizel DM; Vokes EE Semin Radiat Oncol; 2009 Jan; 19(1):11-6. PubMed ID: 19028340 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in the management of squamous cell carcinoma of the head and neck. Kim KB; Khuri FR; Shin DM Expert Rev Anticancer Ther; 2001 Jun; 1(1):99-110. PubMed ID: 12113140 [TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for head and neck cancer. Rhee JC; Khuri FR; Shin DM Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138 [TBL] [Abstract][Full Text] [Related]
13. [Development of treatments for head and neck squamous cell carcinomas]. Tsukuda M Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():85-96. PubMed ID: 10410663 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916 [TBL] [Abstract][Full Text] [Related]
16. New advances in targeted therapies for squamous cell carcinoma of the head and neck. Machiels JP; Schmitz S Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493 [TBL] [Abstract][Full Text] [Related]
17. Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. Scher RL; Esclamado RM Semin Radiat Oncol; 2009 Jan; 19(1):17-23. PubMed ID: 19028341 [TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy in head and neck cancer: a new paradigm. Pointreau Y; Atean I; Fayette J; Calais G; Lefebvre JL Anticancer Drugs; 2011 Aug; 22(7):613-20. PubMed ID: 21160420 [TBL] [Abstract][Full Text] [Related]
19. [Treatment for recurrent head and neck carcinomas]. Tsukuda M Gan To Kagaku Ryoho; 1998 Feb; 25(3):303-8. PubMed ID: 9492820 [TBL] [Abstract][Full Text] [Related]
20. Molecular-targeted therapies in head and neck cancer. Rao SD; Fury MG; Pfister DG Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]